Single-cell transcriptomic characterization of macrophage populations in end-stage lung diseases
作者
Theodore S. Kapellos,Evgeny Chichelnitskiy,Chiara Goracci,Rainer Knoll,Ulas Thomas,Sina Dorn,Jonas Schulte-Schrepping,Matthias Becker,Kristian Händler,Jenny F. Kühne,Jürgen Behr,Joachim Ludwig Schultze,Kerstin Beushausen,Fabio Ius,Lavinia Neubert,Oender Yildirim,Christine Falk
标识
DOI:10.1183/23120541.lsc-2026.oa402
摘要
Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are leading causes of death worldwide, yet the immune mechanisms driving their progression remain incompletely understood. To address this, we integrated single-cell transcriptomics, multi-color flow cytometry, high-dimensional imaging and multiplexed protein profiling to generate a comprehensive map of immune heterogeneity in the lung parenchyma of patients with end-stage emphysema and fibrosis. Our analyses revealed that macrophages are more abundant in fibrotic lungs compared to emphysema and display distinct transcriptional remodeling characterized by the upregulation of lipid localization, transport and wound healing. Utilizing co-expression network analysis, we demonstrated that macrophage-related gene signatures are enriched in IPF versus COPD whole lung transcriptomes, highlighting the immune system’s integral role in the pathophysiology of these diseases and serving as putative biomarkers of outcome prediction. Moreover, alveolar and interstitial macrophages emerged as key intercellular communication hubs, engaging in signaling networks mediated by MIF, MK, APP and UGRP1 pathways alongside canonical pro-fibrotic circuits. Importantly, we detected enriched FGFR1 and FGFR2 gene signatures in macrophages from IPF lungs, supporting the role of FGF-β as a critical regulator of macrophage-driven lung injury and lipid metabolism. Collectively, these findings delineate macrophage-driven pathogenic circuits that differentiate emphysema from fibrosis and highlight immune molecular signatures as promising therapeutic targets in chronic respiratory diseases.